$1.87
1.08%
Nasdaq, Jan 02, 10:03 pm CET
ISIN
US65487U1088
Symbol
NKTX

Nkarta Inc Stock price

$1.87
+0.13 7.47% 1M
+0.13 7.47% 6M
+0.02 1.08% YTD
-0.63 25.20% 1Y
-4.12 68.78% 3Y
-57.74 96.86% 5Y
-46.03 96.10% 10Y
-46.03 96.10% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.02 1.08%
ISIN
US65487U1088
Symbol
NKTX
Industry

Key metrics

Basic
Market capitalization
$132.8m
Enterprise Value
$-149.5m
Net debt
positive
Cash
$282.3m
Shares outstanding
71.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.6
P/B
0.4
Financial Health
Equity Ratio
81.4%
Return on Equity
-26.7%
ROCE
-29.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-112.7m | $-116.6m
EBIT
$-122.0m | $-120.4m
Net Income
$-102.6m | $-98.4m
Free Cash Flow
$-93.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
5.9% | 1.9%
EBIT
5.4% | 5.9%
Net Income
7.6% | 9.7%
Free Cash Flow
13.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.4
FCF per Share
$-1.3
Short interest
20.2%
Employees
109
Rev per Employee
$0.0
Show more

Is Nkarta Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Nkarta Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Nkarta Inc forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Nkarta Inc forecast:

Buy
85%
Hold
15%

Financial data from Nkarta Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
7% 7%
-
- Research and Development Expense 88 88
9% 9%
-
-113 -113
6% 6%
-
- Depreciation and Amortization 9.22 9.22
1% 1%
-
EBIT (Operating Income) EBIT -122 -122
5% 5%
-
Net Profit -103 -103
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nkarta Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nkarta Inc Stock News

Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami.
Positive
Seeking Alpha
about one month ago
Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune diseases, despite current market pessimism. NKX019, the lead CAR-NK candidate, shows promising early preclinical results in B cell depletion and is advancing through Ntrust-1 and Ntrust-2 trials. NKTX boasts a strong cash position, providing over three years of operational runway, supporting continu...
Neutral
GlobeNewsWire
about 2 months ago
Enrollment now underway in second dose-escalation cohort  Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamide Enrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to...
More Nkarta Inc News

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Paul Hastings
Employees 109
Founded 2005
Website www.nkartatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today